Nuevocor
Singapore, SG · 6 known investors
Nuevocor is a clinical-stage biotechnology company developing genetic medicines for cardiomyopathies by targeting their underlying mechanobiology. Its lead program, NVC-001, treats LMNA-related dilated cardiomyopathy, a rare disease with no targeted treatments, with operations across the United States, Europe, and Singapore.
BiotechHealthtech
Founders & leadership
MS
Monica ShahChief Medical Officer
AG
Al GianchettiChief Executive Officer
Investors · 6
In the news
Frequently asked questions
- What does Nuevocor do?
- Nuevocor is a clinical-stage biotechnology company developing genetic medicines for cardiomyopathies by targeting their underlying mechanobiology. Its lead program, NVC-001, treats LMNA-related dilated cardiomyopathy, a rare disease with no targeted treatments, with operations across the United States, Europe, and Singapore.
- Who are Nuevocor's investors?
- Nuevocor's investors include Angelini Ventures, ClavystBio, Kurma Partners, Boehringer Ingelheim Venture Fund, Highlight Capital, SEEDS Capital.
- Where is Nuevocor headquartered?
- Nuevocor is headquartered in Singapore, SG.